Zymeworks is building new cancer drugs, but most of its story still depends on early trial results and partner-led programs that can move faster or slower than expected. Learn why delays or setbacks could strain its cash runway, yet successful readouts and stronger product launches could still create meaningful upside over time.Read more
Zymeworks is leaning on partnerships and a growing cancer drug pipeline to turn research progress into more steady income, but that progress depends heavily on other companies hitting key milestones. See what could lift results if late-stage trial and approval news goes well—and what could derail it if delays, early-stage setbacks, or tougher competition hit first.Read more
Zymeworks could benefit as more cancer treatments shift toward targeted antibody drugs, with its platforms and partners helping push new medicines from the lab toward real-world use. But the story hinges on other companies following through and on early test results holding up, so setbacks in trials, rules, or funding could hit expectations hard.Read more
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
